Imagine a specialized shield that protects the brain from a dangerous mosquito-borne virus. Instead of a one-size-fits-all approach, this project uses AI to design a precise 'key' that fits many different versions of the virus. It's like building a smart security system that recognizes the enemy and trains the body's defenses to stop it before it hits the nervous system.
There is currently no prophylaxis or treatment for West Nile Virus, which is critical given that the fatality rate reaches 30% in people over 60.
AI-designed Envelope-based immunogens, VLP-based formulations, and WNV-specific therapeutic antibodies.
If you are a vaccine manufacturer dealing with the lack of prophylaxis for mosquito-borne diseases — this project developed AI-designed immunogens and Virus Like Particles (VLPs) that protect against neuroinvasion. This allows for the creation of a first-in-class WNV vaccine targeting high-risk groups.
If you are a biotech firm dealing with the need for acute treatments for encephalitis — this project developed WNV-specific antibodies with therapeutic potential. These can be used to treat the 1% of infected individuals who develop severe central nervous system illness.
If you are a health agency dealing with an ageing population where case-fatality rates reach 30% — this project developed a platform for rational vaccine design. This ensures better health security against emerging flaviviruses in elderly populations.
Based on available project data, specific cost or pricing information is not provided.
The project has optimized expression systems in mammalian and insect cells and established purification protocols, which are necessary steps for industrial scaling.
Based on available project data, there is no specific mention of patents or licensing agreements, though the project involves the design of novel immunogens.
The project runs from 2023-12-01 to 2027-11-30, suggesting that clinical validation and market entry would follow this period.
The project intends to integrate social sciences and public health perspectives in future phases to guide communication and vaccine acceptance in elderly populations.
The consortium consists of 8 partners across 4 countries (DE, DK, ES, FR). It is heavily weighted toward research and academia, with 3 universities and 4 research organizations, while industry representation is low at 12% (1 partner). This structure indicates the project is currently in a high-innovation, early-stage R&D phase rather than a commercialization phase.
Contact FUNDACIO PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA (IRSICAIXA) in Spain
Contact us to explore licensing opportunities for AI-designed WNV immunogens.
